Accelerating clinical development in China & the US
China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.
Development and Regulatory Strategy for US and China
This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers. Additionally, it aims to understand the Evolving U.S. regulatory requirements for diversity in clinical cancer trials.
Go/No Go Decisions Based on Early Phase Oncology Trials
Understanding the latest regulatory and clinical developments in the field of Oncology in China, along with discussing the similarities and differences between Chinese oncology market and the overall global market, promote academic exchange and cooperation of the global oncology research and development ecosystem.
Driving efficiencies through virtual trial solutions in Asia Pacific
What is driving the acceleration of clinical trials in the Asia Pacific region and what are key considerations to maximise the opportunity for decentralised clinical trials in the future across the region.
Accelerating Clinical Trials in Rare Disease - Understanding Asia’s success as a rare disease clinical trial location
This webinar looks at Asia’s rare disease clinical trial landscape, why China is an increasingly attractive location for rare disease trials and critical program strategies to consider.
Expedited clinical development strategies for China
A two-part webinar interview and panel discussion with exclusive insights into China’s regulatory environment, the advantages of involving China sites, and strategies to accelerate entry in China.
Asia Pacific: The solution for accelerating your clinical trial program
Presented By Katrina Norial at OCT Southeast. In this presentation Katrina Norial discusses Novotech’s capabilities, ensuring clinical trial continuity during COVID-19 and leveraging regional advantages to accelerate development.
The benefits of running clinical trials in China
During this webinar we will discuss how China offers a significant opportunity for biotech companies to accelerate their clinical development.
Achieving regulatory milestones & meeting commercial goals
Gain exclusive insight into the world of product development planning and regulatory affairs from industry experts to understand the importance of a streamlined and focused global program strategy.
Managing Global Studies with Regional Partners
In this webinar, you'll learn about 1) Working with specialist CRO partners to maintain speed, flexibility, “fit” and regional expertise, 2) Leveraging technology and gold standard systems to provide integrated global management structure and reporting and 3) Advantages and tradeoffs of different global clinical trial setups.
Accelerating Clinical Trials in Australia and Asia – Presented by Steven Roan at OCT USA
Steven Roan breaks down the acceleration of clinical trials in Australia and Asia. The presentation is broken into three main segments. An introduction to Novotech and how Asia-Pacific is handling the COVID-19 pandemic, what Novotech is doing to support companies in these times, and finally talking about the benefits of working in Asia-Pacific for clinical trials.
Running First-in-human and Vaccines Studies in Australia
A US Investigational New Drug (IND) submission is not necessary to initiate first-in-human clinical trials in Australia. FIH trials in Australia are of high quality and are acceptable to other regulatory agencies in support of later Phase clinical trials.